HC Wainwright Has Optimistic Opinion of AGIO FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Agios to a loss of $5.58 per share from a loss of $6.05, maintaining a Buy rating and a $62 price target. The firm projects the company will reach positive EPS of $2.01 in FY2030.
• Agios reported a quarterly loss of $1.09 per share, better than the $1.24 loss analysts expected, and revenue of $55.39 million, above the $51.65 million consensus.
• Analyst views are broadly favorable: MarketBeat reports a Moderate Buy consensus rating and an average price target of $42.12, though ratings include one Sell and three Holds.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Analysts at HC Wainwright increased their FY2026 earnings per share estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($5.58) for the year, up from their previous estimate of ($6.05). HC Wainwright currently has a "Buy" rating and a $62.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' Q4 2026 earnings at ($1.12) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($1.84) EPS, FY2029 earnings at ($0.07) EPS and FY2030 earnings at $2.01 EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.15. The business had revenue of $55.39 million during the quarter, compared to the consensus estimate of $51.65 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.

Several other research firms have also commented on AGIO. TD Cowen raised Agios Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 24th. JPMorgan Chase & Co. increased their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, August 7th. Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Truist Financial lowered their target price on shares of Agios Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Bank of America lifted their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a "buy" rating in a report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $42.12.

Agios Pharmaceuticals Stock Up 6.7%

NASDAQ:AGIO opened at $31.38 on Tuesday. The stock's 50 day moving average price is $33.23 and its 200 day moving average price is $31.78. The company has a market capitalization of $1.87 billion, a PE ratio of -4.97 and a beta of 0.66. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Sei Investments Co. increased its stake in shares of Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company's stock worth $2,150,000 after acquiring an additional 49,198 shares during the period. SCS Capital Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth about $22,743,000. Bank of America Corp DE acquired a new stake in Agios Pharmaceuticals in the second quarter valued at about $18,847,000. Parkman Healthcare Partners LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at about $24,828,000. Finally, Squarepoint Ops LLC boosted its holdings in Agios Pharmaceuticals by 53.7% in the 2nd quarter. Squarepoint Ops LLC now owns 321,138 shares of the biopharmaceutical company's stock valued at $11,917,000 after purchasing an additional 112,250 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments.

Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.

Founded in 2008, Agios initially built a research portfolio in cancer metabolism before shifting its focus to rare genetic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.